Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Dose Escalation, Cohort Study to Determine the Maximum Tolerated Dose and Safety of PEP005 Topical Gel When Applied on Day 1 and Day 2 to Actinic Keratoses on the Shoulders, Chest, Back or Arms Followed by a Post-Treatment Follow-up Period Lasting at Four Weeks

NCT00239135 is registered in ClinicalTrials.gov with Peplin as lead sponsor.

NCT NCT00239135
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00239135 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Dose Escalation, Cohort Study to Determine the Maximum Tolerated Dose and Safety of PEP005 Topical Gel When Applied on Day 1 and Day 2 to Actinic Keratoses on the Shoulders, Chest, Back or Arms Followed by a Post-Treatment Follow-up Period Lasting at Four Weeks
Lead sponsor
Peplin
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2005
Completion date
December 31, 2005
Enrollment
34
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

keratosis